PierisAn alternative investment portfolio could benefit from forward-thinking pharmaceutical stocks. While Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) doesn’t engage in the popular cannabis market, it does have promising biotechnologies that could shape some aspects of healthcare in the future.

Pieris develops and discovers drugs based on anticalin proteins. These artificial proteins mimic the body’s natural antibodies and can be used to treat conditions like anemia, respiratory disease, and cancer.

The biotechnology industry is heavily speculative. Pieris pharmaceuticals has promising drug treatments in the pipeline, but these are subject to testing and validation, as well as approval from the FDA and similar organizations around the world. Institutional investment can be used to gauge confidence in speculative stocks. Institutions currently hold 61.80% of all stock in the company, with private investors making up most of the remainder. Company insiders own just 0.23% of Pieris shares.

While the company spends heavily on research and development, it is also cash-rich. Investments, cash, and equivalents were equal to $110.8 million as of April 1, 2019. This will allow the company to continue to generate revenue from its investments, while spending on the development of its innovative drugs. The company’s financial stability makes this an attractive option for alternative investors.

Key Data:

  • 1 Year Price Growth: -28.85%
  • YTD Price Growth: 92%
  • 3 Month Price Growth: 53%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.